Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.
Noxopharm Limited, a clinical-stage Australian biotech specialising in cancer and inflammation therapies and mRNA safety-enhancing technologies, develops proprietary drugs through its Sofra and Chroma platforms in collaboration with specialist in-house teams and external research partners.
The company has announced the resignation of its CEO and managing director, Dr Gisela Mautner, who joined in 2019 and has led the business since early 2022, overseeing a major strategic shift. Chairman Fred Bart thanked her for her service, and Noxopharm signalled that it expects to name a successor soon, a move that will be closely watched by investors given the company’s evolving direction and clinical ambitions.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotechnology company focused on discovering and developing novel treatments for cancer and inflammation, including technology designed to improve the safety profile of a broad range of mRNA medicines. Leveraging in-house expertise and partnerships with leading researchers, it is building a pipeline of proprietary drugs based on its Sofra platform for inflammation, autoimmunity, mRNA enhancement and oncology, and its Chroma platform for oncology.
Average Trading Volume: 183,843
Technical Sentiment Signal: Sell
Current Market Cap: A$19.66M
Find detailed analytics on NOX stock on TipRanks’ Stock Analysis page.